Proclara Biosciences Overview
- Year Founded
-
2006
- Status
-
Out of Business
- Employees
-
19
- Latest Deal Type
-
Out of Business
Proclara Biosciences General Information
Description
Developer of disease-modifying therapies designed to be used for the treatment of neurodegenerative diseases. The company's therapies recognize and target multiple misfolded proteins, thereby enabling clinicians to make a transformative impact on the lives of patients affected by Alzheimer's, Parkinson's and systemic amyloidosis.
Contact Information
Website
www.proclarabio.comCorporate Office
- 125 CambridgePark Drive
- Suite 301
- Cambridge, MA 02140
- United States
Corporate Office
- 125 CambridgePark Drive
- Suite 301
- Cambridge, MA 02140
- United States
Proclara Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Out of Business | 06-Aug-2021 | Completed | Out of Business | |||
| 11. Secondary Transaction - Private | 31-Jul-2019 | Completed | Generating Revenue | |||
| 10. Later Stage VC (Series F) | 16-Nov-2018 | Completed | Generating Revenue | |||
| 9. Grant | 10-Mar-2017 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series E) | 07-Sep-2016 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series D) | 14-Jan-2015 | Completed | Generating Revenue | |||
| 6. Grant | 19-Dec-2013 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series C) | 06-May-2013 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series B1) | 08-Mar-2012 | $9M | $27M | Completed | Generating Revenue | |
| 3. Later Stage VC (Series B) | 01-Mar-2011 | $12.4M | $19.4M | Completed | Startup |
Proclara Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series F | ||||||||
| Series E | ||||||||
| Series D | 64,244,675 | $0.000100 | 8% | $0.9 | $0.9 | 1x | $0.9 | 18.84% |
Proclara Biosciences Comparisons
Industry
Financing
Details
Proclara Biosciences Competitors (35)
One of Proclara Biosciences’s 35 competitors is CervoMed, a Formerly VC-backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CervoMed | Formerly VC-backed | Boston, MA | ||||
| Cognition Therapeutics | Formerly VC-backed | New York, NY | ||||
| Neurona Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| NeuroNascent | Venture Capital-Backed | Clarksville, MD | ||||
| WaveBreak | Venture Capital-Backed | Boston, MA |
Proclara Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Proclara Biosciences Patents
Proclara Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2019241628-A1 | General amyloid interaction motif (gaim) | Inactive | 15-Jun-2018 | ||
| ES-2910017-T3 | Polypeptides comprising a modified amino acid sequence of bacteriophage g3p lacking a glycosylation signal | Active | 03-Dec-2014 | ||
| AU-2015358504-A1 | Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal | Inactive | 03-Dec-2014 | ||
| AU-2015358504-A8 | Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal | Inactive | 03-Dec-2014 | ||
| CA-2969128-A1 | Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal | Inactive | 03-Dec-2014 | A61K38/162 |
Proclara Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Proclara Biosciences FAQs
-
When was Proclara Biosciences founded?
Proclara Biosciences was founded in 2006.
-
Where is Proclara Biosciences headquartered?
Proclara Biosciences is headquartered in Cambridge, MA.
-
What is the size of Proclara Biosciences?
Proclara Biosciences has 19 total employees.
-
What industry is Proclara Biosciences in?
Proclara Biosciences’s primary industry is Drug Discovery.
-
Is Proclara Biosciences a private or public company?
Proclara Biosciences is a Private company.
-
What is Proclara Biosciences’s current revenue?
The current revenue for Proclara Biosciences is .
-
How much funding has Proclara Biosciences raised over time?
Proclara Biosciences has raised $145M.
-
Who are Proclara Biosciences’s competitors?
CervoMed, Cognition Therapeutics, Neurona Therapeutics, NeuroNascent, and WaveBreak are some of the 35 competitors of Proclara Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
